Skip to content
Arvinas logo
Search
Close
Arvinas logo
Search
Close

Type: Poster Presentation

KRAS-Targeted PROTAC Degraders are Broadly Efficacious Against KRAS Dependent Tumor Models

High throughput screening techniques to inform on compound liability and solubility to advance the PROTAC® platform

A phase 2 expansion study of ARV-766, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer – Poster Presentation

Structural insights into PROTAC®-induced proximity

The Arvinas PROTAC® Discovery Engine: Insights from Discovering & Developing Molecules That Induce Targeted Protein Degradation

PROTAC® Protein Degraders in the Clinic

Orally Administered PROTAC® Molecules Selectively Clear Pathologic Proteins in CNS & Muscle

Outcomes in men with metastatic castration-resistant prostate cancer and tumors with certain androgen receptor (AR) mutations

Real world outcomes in patients with metastatic castration resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations

In Vitro Evaluation Of PROTAC® Degrader ARV-110 (Bavdegalutamide) For Cytochrome P450- And Transporter-Mediated Drug-Drug Interaction

← older
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
Menu
  • Careers
  • Privacy Policy
  • Terms of Use
Linkedin-in Twitter

© 2023 Arvinas. All rights reserved.

Arvinas logo
Search
Close
  • Our Science
    • PROTAC® Discovery Engine
    • Scientific Publications
    • Partnerships
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Research & Development
    • Pipeline
    • Androgen Receptor
    • Estrogen Receptor
    • Neuroscience
  • Careers & Culture
    • Open Positions
    • Life in New Haven
    • Our Values
    • Benefits
    • Giving Back
  • Patients
    • Patients with Breast Cancer
    • Patients with Prostate Cancer
    • Clinical Trials
    • Expanded Access Policy
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Menu
  • Contact Us
Linkedin-in Twitter
Skip to content